Baha M. Arafah, MD, answers our questions about his recent study, which calls into question current practice of administering excessive hydrocortisone supplementation among patients with adrenal...
In this commentary, James Matera, DO, writes about the ESRD treatment choice model that started on January 1, 2021, as well as its importance to and implications for practitioners.
Rashmi Roy, MD, FACS, endocrine surgeon for the University Medical Center of Princeton at Plainsboro, outlines how adrenal tumors can cause patients to display symptoms of hypertension and diabetes.
